Dear Editor, Burkitt lymphoma/leukemia (BL/L) was the first neoplasia associated with rearrangement in MYC that is the molecular hallmark of this disease. Particularly, immunoglobulin genes are associated with MYC in BL/L, where the juxtaposition with heavy chain locus (14q32) or light chain loci (2p12 and 22q11) leads to MYC overexpression, which is believed to play a central role in BL/L pathogenesis [1] .
During investigation of the clinical significance of secondary chromosomal abnormalities in pediatric BL/L, we identified a patient with BL/L without detectable MYC translocation [2] . Here, we aimed to refine cytogenetic and molecular characteristics, such as expression levels of MYC, other genes, and microRNAs, to contribute to the diagnosis of BL/L without MYC translocations. Clinical data are described in Table 1 .
G-banding of bone marrow (BM) cells revealed 46,XY,der(8) in 31.5% of the metaphases analyzed (Fig. 1A) . FISH analysis revealed three MYC signals, two in the derivative chromosome 8, apart from a normal chromosome 8 (Fig. 1B, C) . FISH analysis of BCL6 and BCL2 loci ruled out abnormalities common to other B cell non-Hodgkin lymphomas (NHL) (Fig. 1D) . Multicolor FISH excluded the presence of any other chromosomal abnormality, including changes in chromosome 11, recently associated with MYC-negative BL/L cases in the WHO classification [3] . Multicolor probes helped define the final karyotype as 46,XY,der(8) t(8;8)(qter-> q21::p22-> qter) (Fig. 1E, F) .
In 2006, Hummel et al [4] proposed a molecular signature for BL/L, including in their sample cases with lymphomas lacking MYC rearrangement. Among them, CD10 and BCL2, besides MYC, were found to be differentially expressed and are used as classifiers for BL/L signature. Moreover, supporting the idea of MYC post-transcriptional deregulation in BL/L, some studies have revealed differential expression patterns of specific miRNAs in comparison to that in other NHL [5, 6] itive and BCL2-negative), cells from three BL and two diffuse large B-cell lymphoma cell lines, three reactive follicular hyperplasia lymph nodes, and two normal BM samples were used for comparison.
MYC and BCL2 expression levels in our patient were similar to those in the BL/L group, although BCL2 levels were lower than those observed in all the cases with BL/L (Fig. 1G, H) . Similarly, CD10 levels were lower than those in the BL/L group (Fig. 1I ). These differences are likely to have arisen from the different types of samples used for molecular testing. miR155 and Let7a, 7b, and 7e, which are downregulated by MYC [7] , were in general at low levels in the BL/L group ( Fig. 1J-M ). miR9*, usually downregulated in patients lacking the MYC translocation [6] , was downregulated in our patient as well as in the BL/L group (Fig. 1N ). miR150 and miR21 were downregulated in all the cases (Fig. 1O-P) [7] . Thus, gene expression analysis of our patient suggests a BL-like molecular profile despite the lack of MYC translocation.
To the best of our knowledge, this is the first report on a patient with a partial trisomy 8 lacking the typical t(8;14)(q24;q32), which resulted in three copies of MYC, and MYC overexpression was comparable to that generally found in BL/L. In rare cases, MYC rearrangement cannot be identified [1, 5] , and the gene expression profile appears to be comparable to that observed in BL/L [4] . This suggests that other pathogenic mechanisms could lead to deregulation, such as post-transcriptional control by microRNA, of MYC expression [5, 6] . In this context, since 2008, the WHO classification includes BL/L cases without a demonstrable MYC translocation [3] .
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder associated with an elevated risk (10-30%) of developing malignancies. NHL was the most frequently detected cancer (53 -64%) in patients with A-T [8] ; however, BL/L is rarely reported. Despite its rarity, Sandlund et al [9] suggested that BL/L in patients with A-T tends to carry non-canonical MYC rearrangements, probably because of global chromosome instability. This hypothesis is in agreement with that observed in our patient.
In summary, our results, obtained using molecular cytogenetics and expression approaches, add new information about BL/ L without MYC translocation. Whether the altered MYC expression in our patient resulted from microRNA deregulation, a known alternative pathogenic mechanism [5, 6] , or from trisomy 8, which might result in MYC overexpression by an increased gene dosage, remains to be elucidated.
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